AstraZeneca PLC (AZN)

NASDAQ: AZN · IEX Real-Time Price · USD
62.81
-0.75 (-1.18%)
Feb 2, 2023, 10:22 AM EST - Market open
-1.18%
Market Cap 201.08B
Revenue (ttm) 45.15B
Net Income (ttm) 2.04B
Shares Out 3.20B
EPS (ttm) 0.56
PE Ratio 98.67
Forward PE 18.42
Dividend $2.22 (3.53%)
Ex-Dividend Date Aug 11, 2022
Volume 2,196,156
Open 63.36
Previous Close 63.56
Day's Range 62.57 - 63.39
52-Week Range 52.65 - 72.12
Beta 0.23
Analysts Buy
Price Target 74.78 (+19.06%)
Earnings Date Feb 9, 2023

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 83,100
Stock Exchange NASDAQ
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2021, AstraZeneca's revenue was $37.42 billion, an increase of 40.58% compared to the previous year's $26.62 billion. Earnings were $112.00 million, a decrease of -96.50%.

Financial Statements

Analyst Forecast

According to 39 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $74.78, which is an increase of 19.06% from the latest price.

Price Target
$74.78
(19.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

U.S. Appeals Court Sides With Drugmakers on Discount Program

The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.

Other symbols: NVOSNY
2 days ago - WSJ

TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datop...

3 days ago - Business Wire

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.

5 days ago - Zacks Investment Research

Mergers and Acquisitions in 2023 Off To A Strong Start

Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...

6 days ago - MarketBeat

7 Dividend Stocks to Buy for a Stable Income Stream

A key to successful retirement planning or wealth building is to start early. One critical component of investing is to secure stable cash flows.

Other symbols: CVXLMTNEMTVALEWMT
6 days ago - InvestorPlace

FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants

Many take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them.

6 days ago - CNBC

AstraZeneca's preventive COVID therapy no longer effective against current variants

AstraZeneca AZN, -1.32% AZN, -1.54% said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophyla...

6 days ago - Market Watch

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy indi...

1 week ago - Business Wire

Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso

CARLSBAD, Calif.--(BUSINESS WIRE)--As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based compani...

Other symbols: TMO
1 week ago - Business Wire

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash...

1 week ago - Business Wire

AstraZeneca chair: Health care systems around the world can benefit from investment in technology

Leif Johansson, chairman at AstraZeneca, speaks to CNBC's Karen Tso at Davos 2023.

2 weeks ago - CNBC International TV

FDA approves AstraZeneca's new treatment for people with asthma

AstraZeneca AZN, +0.99% AZN, -0.27% said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee com...

3 weeks ago - Market Watch

AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B

AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.

3 weeks ago - Zacks Investment Research

SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.

NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Co...

Other symbols: CINC
3 weeks ago - PRNewsWire

European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums.

3 weeks ago - Market Watch

AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal

AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline

Other symbols: CINC
3 weeks ago - Barrons

AstraZeneca to Buy U.S. Cardiorenal-Drug Maker

For an initial $1.3 billion, the Anglo-Swedish company will acquire CinCor Pharma, including rights to its baxdrostat cardiorenal drug, which has shown promise in clinical trials.

Other symbols: CINC
3 weeks ago - WSJ

AstraZeneca will buy U.S.-based CinCor for cardiorenal asset

AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug for an upfront transaction value of around $1.3 billion.

Other symbols: CINC
3 weeks ago - Market Watch

AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal

AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.

Other symbols: CINC
3 weeks ago - Reuters

AstraZeneca's COVID drug Evusheld unlikely to neutralize newest variant, FDA says

The Food and Drug Administration late Friday said that AstraZeneca Plc's AZN, +1.42% COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one ...

3 weeks ago - Market Watch

FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA

The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.

3 weeks ago - Zacks Investment Research

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZ...

1 month ago - Business Wire

ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer

TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxte...

1 month ago - Business Wire

AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers

The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.

1 month ago - Zacks Investment Research

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

1 month ago - Zacks Investment Research